Emergence of *Clostridium difficile* infection in tuberculosis patients due to a highly rifampicin-resistant PCR ribotype 046 clone in Poland

P. Obuch-Woszczatyński · G. Dubiel · C. Harmanus · E. Kuijper · U. Duda · D. Wultańska · A. van Belkum · H. Pituch

Received: 31 January 2013 / Accepted: 14 February 2013 / Published online: 27 February 2013
© The Author(s) 2013. This article is published with open access at Springerlink.com

**Abstract** *Clostridium difficile* infection (CDI) is a major cause of nosocomial diarrhea. CDI is known to develop after antibiotic administration, but anti-tuberculosis agents have rarely been implicated. We documented an outbreak caused by a highly rifampicin-resistant *C. difficile* strain of polymerase chain reaction (PCR) ribotype 046 in patients with active tuberculosis.

**Introduction**

*Clostridium difficile* infection (CDI), the most common infectious cause of hospital-acquired diarrhea, is usually preceded by the use of antibiotics such as fluoroquinolones (FQ), cephalosporins, broad-spectrum penicillins, and clindamycin [1]. Anti-tuberculosis drugs are not commonly associated with the development of CDI [2–5]. Recently, FQ have been linked to CDI, particularly those cases caused by polymerase chain reaction (PCR) ribotype 027 [6, 7]. The objective of our study was to determine the characteristics of *C. difficile* isolates associated with an outbreak of infection in a tuberculosis unit. Patients were hospitalized in the Specialized Hospital of Lung Diseases and Tuberculosis (SHLDT) in Bystra, South Poland. The clinical findings were also assessed.

**Materials and methods**

**Setting and study design**

This study was conducted in the 250-bed SHLDT harboring a 46-bed tuberculosis unit, located in South Poland. During the study period, a total of 8,158 patients were hospitalized in the SHLDT. From September 2009 through December 2010, CDI was suspected in 23 symptomatic patients. CDI was diagnosed in ten patients, corresponding to an incidence of 12.3/10,000 patients admitted to the SHLDT. From September 2009 through December 2010, CDI was suspected in 23 symptomatic patients. CDI was diagnosed in ten patients, corresponding to an incidence of 12.3/10,000 patients admitted to the SHLDT. CDI was diagnosed by an immunoenzymatic assay (*C. difficile* TOX A/B II, TechLab, Blacksburg, VA, USA) and *C. difficile* culture for patients who developed diarrhea. The clinical characteristics of the ten patients were observed prospectively and *C. difficile* isolates from the patients were collected for further study.

**Definition of CDI**

Diarrhea was defined as the passage of three or more unformed stools in 24 h or less. CDI was diagnosed when patients had diarrhea and *C. difficile* toxin(s) was/were detected in fecal samples and/or cultures revealed the presence of *C. difficile*. We defined hospital-acquired CDI...
(HA-CDI) when diarrhea developed at least 48 h after hospitalization or within 2 months of hospital discharge if a patient had a complicated clinical status involving admission to the Intensive Care Unit or surgical intervention [8].

Data collection

The clinical data collected in this study were age, length of hospitalization, medication history, underlying conditions, and the use of antibiotics or chemotherapeutics, especially anti-tuberculosis medication. All adults (mean age 64.3 years) who were suspected of CDI hospitalized at the SHLDT in the period between September 09, 2009 and December 31, 2010 were included in the study. Stool characteristics, frequency of defecation, and abdominal pain were monitored.

Microbiological studies

All fecal samples from ten *C. difficile* toxin-positive diarrheic patients were inoculated anaerobically on *C. difficile*-selective cycloserine–cefoxitin agar plates (CLO, bioMérieux SA, Marcy l’Étoile, France). Colonies were identified as *C. difficile* on the basis of characteristic growth on selective medium, yellow-green fluorescence under UV light (365 nm), the specific odor, and API 20A (bioMérieux SA, Marcy l’Étoile, France). PCR assays to detect *tcdA* and *tcdB* genes and the specific deletion in the *tcdA* gene were conducted as previously described [9]. Primers described by Stubbs et al. were used for amplification of the binary toxin genes *cdtA* and *cdtB* [10]. Three strains were included in this study as controls: toxigenic *C. difficile* VPI 10463 (A+B+), non-toxigenic *C. difficile* NIHBRRIGS 8050 (A–B–), and *C. difficile* GAI 95601 (A–B+) (from H. Kato, Institute of Anaerobic Bacteriology, Gifu University School of Medicine, Gifu, Japan). PCR ribotyping was performed as described by Stubbs et al. [11]. Banding patterns were compared with those of the library of PCR ribotypes at the Anaerobe Reference Laboratory (ARU), Cardiff, Wales, UK. Strains belonging to different PCR ribotypes were used as internal controls.

Antimicrobial drug susceptibility testing

Cultures of *C. difficile* strains on Columbia agar plates (bioMérieux SA, Marcy l’Étoile, France) were suspended and adjusted to an OD950 of 1 on the McFarland scale (using a bioMérieux ATB1550 densitometer) and grown as lawns on Brucella agar plates. Plastic strips (E-test, bioMérieux SA, Marcy l’Étoile, France) with gradients of antibiotics, clindamycin (CL), erythromycin (EM), ciprofloxacin (CI), moxifloxacin (MX), metronidazole (MTZ), vancomycin (VA), and rifampicin (RI), were placed on each plate and incubated anaerobically at 37 °C for 48 h, according to the manufacturer’s instructions. According to the Clinical and Laboratory Standards Institute (CLSI) recommendations [12], antibiotic resistance was defined as follows: minimum inhibitory concentration (MIC) ≥8.0 mg/L for clindamycin and erythromycin, MIC ≥4.0 mg/L for ciprofloxacin and moxifloxacin. Resistance to metronidazole and vancomycin was defined according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST): for metronidazole MIC≥1 mg/L and for vancomycin MIC>2 mg/L [13]. No CLSI guidelines exist for determining the susceptibility of *C. difficile* to the rifamycins, so these ranges were determined based on the natural breakpoints observed previously, and rifampin susceptibility was categorized according to the MICs determined (≤0.002 μg/mL, 0.003–32 μg/mL, and >32 mg/L) [14]. Quality control strains (Bacteroides fragilis NCTC 11295, B. thetaotaomicron ATCC 29741, Escherichia coli ATCC 25922, and Staphylococcus aureus ATCC 25923) were always included.

Results

Clinical findings

The demographic data, medication history, and clinical and laboratory characteristics of CDI are presented in Table 1. Ten patients with an age range from 48 to 86 years (median age 64.3 years) were diagnosed with a CDI between September 2009 and December 2010. There were four women and six men: six patients were hospitalized in the tuberculosis unit and four patients in other units: pulmonary (n=2), internal medicine (n=1), and thoracic surgery (n=1). Of the ten patients, five had active pulmonary tuberculosis as diagnosed by sputum smear and culture. These patients were treated with anti-tuberculosis agents, including isoniazid, rifampicin, and pyrazinamide. Watery diarrhea was observed in all patients, and provided the major clinical manifestation. Three patients developed CDI recurrence. Five patients died because of CDI and the attributed mortality was 50 % (5/10).

Microbiological analysis

Ten *C. difficile* strains were available for investigation. All ten isolates contained *tcdA* and *tcdB* genes. The PCR detecting the repeated sequences in the toxin A gene was positive for a single isolate and generated a 700-bp product similar to that obtained for the Japanese control GAI 95601 *C. difficile* strain. PCR ribotyping classified the ten isolates according to their ribotypes: 046 (n=7), 001 (n=1), 002 (n=1), and 017 (n=1). All strains were resistant to
ciprofloxacin (CI; MIC ≥ 32 mg/L), eight strains to moxifloxacin (MX; MIC ≥ 32 mg/L), seven strains to clindamycin (CM; MIC ≥ 256 mg/L) and erythromycin (EM; MIC ≥ 256 mg/L), and seven to rifampicin (RI; MIC ≥ 32 mg/L). All strains were susceptible to metronidazole (MZT; MIC range 0.047–0.38 mg/L). The MIC range for vancomycin (VA) was 0.75–1 mg/L. Three strains had reduced susceptibility to vancomycin (MIC = 1 mg/L) (according to the EUCAST breakpoints). All strains belonging to PCR ribotype 046 were highly resistant to moxifloxacin, clindamycin, erythromycin, and rifampicin.

### Discussion

CDI caused by *C. difficile* is a major hospital problem. During the past decade, the hypervirulent ribotype 027 strain, expressing the binary toxin, caused outbreaks in North America and Europe [6, 7]. PCR ribotype 046 was less commonly detected in a European survey performed in 2008; it was found in 2% of all the tested isolates, whereas types 014/020, 001, and 078 belonged to the most frequently encountered types [8]. Only five strains belonging to PCR ribotype 046 were found in the University Hospital in Warsaw, Poland, between 2004 and 2006 [9]. All historic strains

### Table 1

Clinical summary for ten cases of *Clostridium difficile* infection (CDI) in the Specialized Hospital of Lung Diseases and Tuberculosis (SHLDT) in Bystra, South Poland

| Date of hospitalization | Age (years)/sex/number of strain | Unit | Underlying diseases | Anti-TB drugs | Other AB | Date of diagnostic CDI | Symptoms of CDI | Fatality associated with CDI | PCR ribotype/ rifampicin RI (R) or RI (S) |
|-------------------------|----------------------------------|------|---------------------|---------------|----------|------------------------|----------------|-----------------------------|-----------------------------------------|
| 27.11.09–17.12.09       | 82/F/CD14                        | TBU  | Non-active TB, atherosclerosis, hypertension | –             | AMOX    | 09.12.09              | Diarrhea, hypovolemic shock, extreme dehydration | Yes                          | 046/RI (R)                          |
| 13.10.09–04.01.10       | 86/F/CD12                        | TBU  | AP TB, chronic congestive heart diseases | RI, I        | CI       | 09.12.09              | Recurrent diarrhea, heart failure (associated with CDI) | Yes                          | 046/RI (R)                          |
| 03.11.09–08.01.10       | 80/F/CD15                        | TBU  | AP TB, failure, chronic obstructive pulmonary disease, cirrhosis of the liver | RI, I, P     | –        | 11.12.09              | Diarrhea                               | –                            | 046/RI (R)                          |
| 19.11.09–02.02.10       | 48/M/CD13                        | TBU  | AP TB, alcoholism, cirrhosis of the liver | RI, I, P     | –        | 09.12.09              | Recurrent diarrheal, neurological symptoms (associated with CDI) | Yes                          | 046/RI (R)                          |
| 17.02.09–09.04.10       | 67/F/CD18                        | TBU  | AP TB, lung empyema, cirrhosis of the liver | RI, I, P     | –        | 30.12.09              | Recurrent severe diarrhea               | Yes                          | 046/RI (R)                          |
| 19.11.09–12.02.10       | 51/M/CD4                         | TBU  | AP TB, pulmonary mycetoma | RI, I, P     | CI       | 12.01.10              | Diarrhea                               | –                            | 046/RI (R)                          |
| 04.02.10–03.03.10       | 86/M/CD22                        | INT  | Respiratory systems diseases | –             | AMOX, CI | 25.02.10              | Diarrhea                               | –                            | 046/RI (R)                          |
| 17.03.10–25.03.10       | 72/MCD30                        | PUL  | Pneumonia, lung empyema | –             | AMOX, CI, CM, MZN | 22.03.10              | Severe diarrhea                         | Yes                          | 017/RI (R)                          |
| 29.11.10–05.02.11       | 88/M/CD61                        | PUL  | Pneumonia, chronic obstructive pulmonary renal failure | –             | AMOX, TX | 30.12.10              | Diarrhea                               | –                            | 001/RI (S)                          |
| 14.09.10–23.09.10       | 69/M/CD50                        | TS   | Lung tumor | –             | CEF      | 23.09.10              | Diarrhea                               | –                            | 002/RI (S)                          |

**Note:**
- **RI** antibiotics, **CDI C. difficile infection**, **TBU tuberculosis unit**, **INT internal unit**, **PUL pulmonology**, **TS thoracic surgery**, **TB tuberculosis**, **AP TB active pulmonary tuberculosis**, **RI rifampicin**, **I isoniazid**, **P pyrazinamide**, **AMOX amoxicillin**, **CI ciprofloxacin**, **CM clindamycin**, **MZN metronidazole**, **TX trimethoprim/sulfamethoxazole**, **CEF cefazolin (perioperative prophylaxis)**, **RI (R) rifampicin resistant, RI (S) rifampicin sensitive**
were highly resistant to clindamycin and erythromycin (MICs ≥256 mg/L), but fully susceptible to moxifloxacin and rifampicin (unpublished data). In our present study, resistance to moxifloxacin was found in all strains belonging to PCR ribotype 046. Resistance to newer fluoroquinolones has been described not only in the hypervirulent strain 027, but also in other emerging PCR ribotypes circulating in hospital settings [15, 16].

Anti-tuberculosis agents are very rarely associated with CDI [2–4]. Agents such as isoniazid and pyrazinamide have little or no effect on the intestinal flora, but rifampicin has an antibiotic effect on a wide range of bacteria [17]. *Clostridium difficile* is usually highly resistant to rifampicin, and rifamycin derivatives have been used for CDI treatment [18]. The emergence of rifampicin-resistant *C. difficile* has been reported in patients with prolonged rifampicin use [19]. In our study, all PCR ribotype 046 strains isolated from patients with prolonged rifampicin therapy were highly resistant to this drug. Multidrug resistance (i.e., resistance to clindamycin, moxifloxacin, and rifampin) was limited primarily to ribotype 027 isolates [16].

Our findings suggested that: (1) patients who are treated with anti-tuberculosis agents, especially rifampicin, who develop acute diarrhea during or after therapy should be evaluated for CDI, (2) treatment with rifampicin can lead to high-level resistance to rifampicin in *C. difficile* strains, (3) the emergence of multidrug-resistant *C. difficile* PCR ribotype 046 may be detrimental to anti-tuberculosis chemotherapy.

Acknowledgments This work was supported by the National Science Centre, grant no. 3G27.

Conflict of interest The authors declare that they have no conflicts of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Brazier JS (1998) The epidemiology and typing of *Clostridium difficile*. J Antimicrob Chemother 41(Suppl C):47–57
2. Jung SW, Jeon SW, Do BH, Kim SG, Ha SS, Cho CM, Tak WY, Kweon YO, Kim SK, Choi YH, Cha SI (2007) Clinical aspects of rifampicin-associated pseudomembranous colitis. J Clin Gastroenterol 41:38–40
3. Chen TC, Lu PL, Lin WR, Lin CY, Wu JY, Chen YH (2009) Rifampin-associated pseudomembranous colitis. Am J Med Sci 338:156–158. doi:10.1097/MAS.0b013e3181f91ce
4. Choi YI, Kim HG, Choi YA, Joo WC, Son DW, Kim CH, Shin YW, Kim YS (2009) A case of pseudomembranous colitis associated with rifampicin therapy in a patient with rectal cancer and gastrointestinal tuberculosis. Korean J Gastroenterol 53:53–56
5. Yim SY, Koo JS, Kim YJ, Park SJ, Kim JN, Jung SW, Yim HJ, Lee SW, Choi JH, Kim CD (2011) Rifampin-induced pseudomembranous colitis with rectosigmoid sparing. Clin Endosc 44:137–139. doi:10.5946/ce.2011.44.2.137
6. Kuipper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, Drudy D, Fitzpatrick F, Wiuff C, Brown DJ, Coia JE, Pituch H, Reichert P, Even J, Mossong J, Widmer AF, Olsen KE, Allerberger F, Notermans DW, Delmée M, Coignard B, Wilcox M, Patel B, Frei R, Nagy E, Bouza E, Marin M, Akerlund T, Virolainen-Julkunen A, Lyytikäinen O, Kotila S, Ingebretsen A, Smyth B, Rooney P, Poxton IR, Monnet DL (2008) Update of *Clostridium difficile* infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13(31). pii: 18942
7. Clements AC, Magalhães RJ, Tatem AJ, Paterson DL, Riley TV (2010) *Clostridium difficile* PCR ribotype 047: assessing the risks of further worldwide spread. Lancet Infect Dis 10:395–404. doi:10.1016/S1473-3099(10)70080-3
8. Bauer MP, Notermans DW, van Benthem BH, Brazier JS, Wilcox MH, Rumpnik M, Monnet DL, van Dissel JT, Kuipper EJ; ECDIS Study Group (2011) *Clostridium difficile* infection in Europe: a hospital-based survey. Lancet 377:63–73. doi:10.1016/S0140-6736(10)61266-4
9. Pituch H, Brazier JS, Obuch-Woszczyńska P, Wultańska D, Meisel-Mikolajczyk F, Luczk M (2006) Prevalence and association of PCR ribotypes of *Clostridium difficile* isolated from symptomatic patients from Warsaw with macrolide–lincosamide–streptogramin B (MLSB) type resistance. J Med Microbiol 55:207–213
10. Stubbs S, Rumpnik M, Gibert M, Brazier J, Duerten B, Popoff M (2000) Production of actin-specific ADF-ribosyltransferase (binary toxin) by strains of *Clostridium difficile*. FEMS Microbiol Lett 186:307–312
11. Stubbs SL, Brazier JS, O’Neill GL, Duerten BI (1999) PCR targeted to the 16S–23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463
12. Clinical and Laboratory Standards Institute (CLSI) (2007) Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard—7th edition. CLSI document M11-A7. CLSI, Wayne, PA
13. European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2012) Breakpoint tables for interpretation of MICs and zone diameters. Version 2.0, valid from 2012-01-01
14. Curry SR, Marsh JW, Shutt KA, Muto CA, O’Leary MM, Saul MI, Pasculle AW, Harrison LH (2009) High frequency of rifampin resistance identified in an epidemic *Clostridium difficile* clone from a large teaching hospital. Clin Infect Dis 48:425–429. doi:10.1086/596315
15. Pituch H, Obuch-Woszczyńska P, Wultańska D, Nurzyńska G, Harmanus C, Banaszkiewicz A, Radzikowski A, Luczk M, van Belkum A, Kuipper E (2011) Characterisation and antimicrobial susceptibility of *Clostridium difficile* strains isolated from adult patients with diarrhoea hospitalized in two university hospitals in Poland, 2004–2006. J Med Microbiol 60:1200–1205. doi:10.1099/jmm.0.029801-0
16. Tenover FC, Tickler IA, Persing DH (2012) Antimicrobial-resistant strains of *Clostridium difficile* from North America. Antimicrob Agents Chemother 56:2929–2932. doi:10.1128/AAC.00220-12
17. Nakajima A, Yajima S, Shirakura T, Ito T, Katoa Y, Ueda K, Nagoshi D, Kanemoto H, Matsuhashi N (2000) Rifampicin-associated pseudomembranous colitis. J Gastroenterol 35:299–303
18. Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL (2008) Rifamycin antibiotics for treatment of *Clostridium difficile*-associated diarrhea. Ann Pharmacother 42:827–835. doi:10.1345/aph.1K675
19. Choi JM, Kim HH, Park SJ, Park MI, Moon W (2011) Development of pseudomembranous colitis four months after initiation of rifampicin. Case Rep Gastroenterol 5:45–51. doi:10.1159/000323753